Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

NCT07756359 on ClinicalTrials.gov · last registry update 2026-08-10

A small phase 4 — 20 participants, against a typical 75. Due to report September 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Proportion of patients achieving a decrease of the average daily bowel frequency by 30% at week 12 (Week 16 if applicable). Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of North Carolina, Chapel Hill
Sponsor type: Other
Enrollment: 20
Started: 2026-09
Primary completion: 2027-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion of patients achieving a decrease of the average daily bowel frequency by 30% at week 12 (Week 16 if applicable)

Conditions studied

Pouch, Ileal · Pouches, Ileoanal · Bowel Diseases, Inflammatory

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.